CIRCHIPK2-LNP

1 paper2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: Fundamental Research Funds for the Central Universities of Beijing University of Chemical Technology and 2 more

Animals1

Outcomes

Cellular senescence

downin mice1

1 study

CIRCHIPK2-LNP decreases cellular senescence in mice.
“Intra-articular administration of circHIPK2-LNP attenuated chondrocyte senescence and alleviated OA progression in DMM mice.”
Animalsin DMM micecartilage
YTH N6-methyladenosine RNA binding protein 2 mediated m⁶A modification of circHIPK2 promotes cellular senescence and osteoarthritis progression by inhibiting autophagy
Molecular biomedicine27 Mar 2026

Latest

1 in 12 months

Molecular Biomedicine27 Mar

YTH N6-methyladenosine RNA binding protein 2 mediated m⁶A modification of circHIPK2 promotes cellular senescence and osteoarthritis progression by inhibiting autophagy

Experiments in miceOsteoarthritis

Paper

CIRCHIPK2-LNP

Outcomes

Latest

YTH N6-methyladenosine RNA binding protein 2 mediated m⁶A modification of circHIPK2 promotes cellular senescence and osteoarthritis progression by inhibiting autophagy

Related